Exjade (Deferasirox) is on its way!

The Pharmaceutical Benefits Advisory Committee has approved the oral iron chelator Exjade (deferasirox) to be listed on the Pharmaceutical Benefits scheme. Those that are blood transfusion dependant this is a huge step foward in the their treatment regime. For further information click on the following link July 2006 PBAC Outcomes- Positive Recommendations.

Although listed, further steps are to be undertaken which include pricing and approval by the Federal Minister of Health and Ageing.

More information on Exjade (deferasirox)